![](/img/cover-not-exists.png)
PCN12 IMPACT OF ADJUVANT CHEMOTHERAPY WITH DOCETAXEL FOR EARLY BREAST CANCER: COST-EFFECTIVENESS ANALYSIS (CEA) OF A DOCETAXEL, DOXORUBICIN AND CYCLOPHOSPHAMIDE REGIMEN (TAC) VERSUS 5-FLUOROURACIL, DOXORUBICIN AND CYCLOPHOSPHAMIDE (FAC) IN FRANCE
H Miadi-Fargier, C Le Pen, MC Woronoff-Lemsi, JP Guastalla, X Pivot, H Roché, F Pinguet, B Favier, J Gligorov, I Debrix, M Spielmann, EC Antoine, M Cadilhac, GA De PouvourvilleVolume:
8
Year:
2005
Language:
english
DOI:
10.1016/s1098-3015(10)67250-6
File:
PDF, 81 KB
english, 2005